Follow Healthline   |   Healthline on TwitterTwitter   |   Healthline on FacebookFacebook
Symptom Search   |   Treatment Search   |   Doctor Search   |   Drug Search

Constipation : News

Advertisement
Marketplace
Poor skin, dull hair, bad breath, constipation, bloating and general sluggishness are all signs that your body is in need of a good detox.
Source:IcWales
Date:September 28, 2009
No one talks about it but around 15 per cent of New Zealanders have chronic constipation and very few of them seek help.
Source:The New Zealand Herald
Date:September 27, 2009
The pale green vegetable has numerous health benefits. The cooked vegetable is diuretic, sedative and anti-bilious. It gives a feeling of relaxation and is useful in treating urinary disorders.
Source:Sify
Date:September 26, 2009
In order to have proper digestion and a fast metabolism, regular consumption of fibre and water is essential.
Source:Canada.com
Date:September 23, 2009
Q: What can we do about constipation? A: What's considered normal frequency for bowel movements varies widely.
Source:DNJ.com
Date:September 23, 2009
AstraZeneca and Nektar Therapeutics announced today that they have entered into an exclusive worldwide license agreement for two drug development programmes: NKTR-118, a late stage investigational product being evaluated for the treatment of opioid-induced constipation, and the NKTR-119 programme, an early stage programme that is intended to ...
Source:India eNews
Date:September 22, 2009
Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.'s OpRA III drug candidate, which has a range of potential uses.
Source:IBJ.COM
Date:September 22, 2009
Nektar Therapeutics Inc. will end the year flush with cash, after entering a deal valued at $1.5 billion with AstraZeneca plc.
Source:BioWorld
Date:September 21, 2009
AstraZeneca has penned a licensing deal with a US biotechnology group that could see the UK's second biggest drugs group pay up to $735m for two constipation treatments.
Source:The Independent
Date:September 21, 2009
Nectar Therapeutics said today that it licensed a pair of experimental pain treatments to AstraZeneca PLC in a deal valued at about $1.12 billion.
Source:Philly.com
Date:September 21, 2009
Advertisement
Back to Top